financetom
Business
financetom
/
Business
/
F5 Insider Sold Shares Worth $412,154, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
F5 Insider Sold Shares Worth $412,154, According to a Recent SEC Filing
May 26, 2025 1:35 AM

04:56 PM EDT, 05/05/2025 (MT Newswires) -- Chad Michael Whalen, Executive Vice President, Worldwide Sales, on May 01, 2025, sold 1,532 shares in F5 (FFIV) for $412,154. Following the Form 4 filing with the SEC, Whalen has control over a total of 27,310 common shares of the company, with 27,310 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1048695/000104869525000083/xslF345X05/wk-form4_1746478470.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
US agency streamlining self-driving car exemption reviews
US agency streamlining self-driving car exemption reviews
Jun 13, 2025
WASHINGTON, June 13 (Reuters) - The National Highway Traffic Safety Administration on Friday said it was streamlining reviews of requests filed by automakers seeking to deploy self-driving vehicles without required human controls like steering wheels, brake pedals or mirrors. NHTSA has authority to grant petitions to allow up to 2,500 vehicles per manufacturer to operate on U.S. roads without required...
Astria Therapeutics Says New Data Back Navenibart Dose Regimen for Hereditary Angioedema
Astria Therapeutics Says New Data Back Navenibart Dose Regimen for Hereditary Angioedema
Jun 13, 2025
08:00 AM EDT, 06/13/2025 (MT Newswires) -- Astria Therapeutics ( ATXS ) said Friday that initial results from its ongoing long-term open-label trial of navenibart in hereditary angioedema showed a significant reduction in monthly attack rates, supporting the potential for dosing schedules of every three or six months. The biopharmaceutical company said navenibart demonstrated an overall attack-freedom of 50% over...
Arvinas Says ARV-393 Preclinical Studies Show 'Significant' Single-Agent Activity in Certain Lymphoma
Arvinas Says ARV-393 Preclinical Studies Show 'Significant' Single-Agent Activity in Certain Lymphoma
Jun 13, 2025
08:00 AM EDT, 06/13/2025 (MT Newswires) -- Arvinas ( ARVN ) said Friday that its experimental ARV-393 showed significant single-agent activity in a certain type of cell lymphoma, based on data from preclinical studies. The results cover activity in patient-derived xenograft model of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type and PDX models of transformed follicular lymphoma. When combined with oral...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved